Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-Specific mRNA in human tissues

Drug Metabolism and Disposition

Volumn 35, Issue 5, 2007, Pages 721-727

  Husain, Anwar ^a   Zhang, Xiaoyan ^a   Doll, Mark A ^a   States, J Christopher ^a   Barker, David F ^a   Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ARTICLE; CARCINOGENESIS; CELL LINE; CONTROLLED STUDY; EXON; GENE AMPLIFICATION; GENE EXPRESSION; GENE STRUCTURE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CACO-2 CELLS; CELL LINE; CELL LINE, TUMOR; COLON; FEMALE; GENE EXPRESSION PROFILING; HT29 CELLS; HUMANS; INTESTINE, SMALL; KIDNEY; LIVER; LUNG; MALE; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; SPLEEN; TESTIS; TRANSCRIPTION INITIATION SITE; UTERUS;

EID: 34247323530     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.014621     Document Type: Article

References (35)

1. Barker DF, Husain A, Neale JR, Martini BD, Zhang X, Doll MA, States JC, and Hein DW (2006) Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet Genomics 16:515-525.
2. Bendriss EK, Bechtel YC, Paintaud G, Brientini MP, Mantion G, Miguet JP, Bennani A, and Bechtel PR (1998) Acetylation polymorphism expression in patients before and after liver transplantation: influence of host/graft genotypes. Pharmacogenetics 8:201-209.
3. Blum M, Grant DM, McBride W, Heim M, and Meyer UA (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9:193-203.
4. Boukouvala S and Fakis G (2005) Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev 37:511-564.
5. Boukouvala S and Sim E (2005) Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 96:343-351.
6. Butcher NJ, Arulpragasam A, Goh HL, Davey T, and Minchin RF (2005) Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem J 387:119-127.
7. Butcher NJ, Boukouvala S, Sim E, and Minchin RF (2002) Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2:30-42.
8. Carreon T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, et al. (2006) NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer 118:161-168.
9. Coroneos E and Sim E (1993) Arylamine N-acetyltransferase activity in human cultured cell lines. Biochem J 294 (Pt 2):481-486.
10. Deguchi T (1992) Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 267:18140-18147.
11. Ebisawa T and Deguchi T (1991) Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun 177: 1252-1257.
12. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366:649-659.
13. Grant DM, Morike K, Eichelbaum M, and Meyer UA (1990) Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Investig 85:968-972.
14. Hein DW (2006) N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplo-type on urinary bladder cancer risk. Oncogene 25:1649-1658.
15. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, and Feng Y (2000b) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev 9:29-42.
16. Hein DW, Doll MA, Nerland DE, and Fretland AJ (2006) Tissue distribution of N-acetyltransferase 1 and 2 catalyzing the N-acetylation of 4-aminobiphenyl and O-acetylation of N-hydroxy-4-aminobiphenyl in the congenic rapid and slow acetylator Syrian hamster. Mol Carcinog 45:230-238.
17. Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, and Weber WW (2000a) Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 28:1425-1432.
18. Husain A, Barker DF, States JC, Doll MA, and Hein DW (2004) Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 14:397-406.
19. Kent WJ (2002) BLAT - the BLAST-like alignment tool. Genome Res 12:656-664.
20. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, and Haussler D (2002) The human genome browser at UCSC. Genome Res 12:996-1006.
21. Lilla C, Verla-Tebit E, Risch A, Jager B, Hoffmeister M, Brenner H, and Chang-Claude J (2006) Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomark Prev 15:99-107.
22. Loehle JA, Cornish V, Wakefield L, Doll MA, Neale JR, Zang Y, Sim E, and Hein DW (2006) N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J Pharmacol Exp Ther 319:724-728.
23. McQueen CA and Chau B (2003) Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity. Toxicol Sci 73:279-286.
24. Moslehi R, Chatterjee N, Church TR, Chen J, Yeager M, Weissfeld J, Hein DW, and Hayes RB (2006) Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics 7:819-829.
25. Ohsako S and Deguchi T (1990) Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 265:4630-4634.
26. Shyamsundar R, Kim YH, Higgins JP, Montgomery K, Jorden M, Sethuraman A, van de Rijn M, Botstein D, Brown PO, and Pollack JR (2005) A DNA microarray survey of gene expression in normal human tissues. Genome Biol 6:R22.
27. Sim E, Payton M, Noble M, and Minchin R (2000) An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum Mol Genet 9:2435-2441.
28. Suzuki Y, Yamashita R, Nakai K, and Sugano S (2002) DBTSS: database of human transcriptional start sites and full-length cDNAs. Nucleic Acids Res 30:328-331.
29. Turesky RJ, Lang NP, Butler MA, Teitel CH, and Kadlubar FF (1991) Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 12: 1839-1845.
30. Weber WW and Hein DW (1985) N-acetylation pharmacogenetics. Pharmacol Rev 37:25-79.
31. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, DiCuccio M, Edgar R, Federhen S, et al. (2006) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 34:D173-D180.
32. Williams JA (2001) Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis 22:209-214.
33. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, and McManus ME (2000) Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 54:19-29.
34. Yamashita R, Suzuki Y, Wakaguri H, Tsuritani K, Nakai K, and Sugano S (2006) DBTSS: database of human transcription start sites, progress report 2006. Nucleic Acids Res 34:D86-D89.
35. Zang Y, Zhao S, Doll MA, States JC, and Hein DW (2004) The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14:717-723.